Cargando…
MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease
In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows t...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145033/ https://www.ncbi.nlm.nih.gov/pubmed/32352717 http://dx.doi.org/10.14309/ctg.0000000000000134 |
_version_ | 1783519930963984384 |
---|---|
author | Cordes, Friederike Demmig, Claudia Bokemeyer, Arne Brückner, Markus Lenze, Frank Lenz, Philipp Nowacki, Tobias Tepasse, Phil Schmidt, Hartmut H. Schmidt, M. Alexander Cichon, Christoph Bettenworth, Dominik |
author_facet | Cordes, Friederike Demmig, Claudia Bokemeyer, Arne Brückner, Markus Lenze, Frank Lenz, Philipp Nowacki, Tobias Tepasse, Phil Schmidt, Hartmut H. Schmidt, M. Alexander Cichon, Christoph Bettenworth, Dominik |
author_sort | Cordes, Friederike |
collection | PubMed |
description | In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis. METHODS: The miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems. RESULTS: When compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r(2) = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0–1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001). DISCUSSION: MiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. |
format | Online Article Text |
id | pubmed-7145033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-71450332020-04-17 MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease Cordes, Friederike Demmig, Claudia Bokemeyer, Arne Brückner, Markus Lenze, Frank Lenz, Philipp Nowacki, Tobias Tepasse, Phil Schmidt, Hartmut H. Schmidt, M. Alexander Cichon, Christoph Bettenworth, Dominik Clin Transl Gastroenterol Article In patients with inflammatory bowel disease (IBD), a treat-to-target treatment strategy requires tight monitoring of disease activity. Noninvasive biomarkers may help to monitor the intestinal disease activity. We demonstrated recently that peripheral microRNA (miR)-320a expression in mice follows the course of experimental colitis. The aim of this study was to evaluate the potential of miR-320a to monitor the disease activity in patients with IBD, to predict the course of disease, and to distinguish IBD from infectious colitis. METHODS: The miR-320a levels were prospectively assessed by quantitative real-time polymerase chain reaction analysis of peripheral blood samples from 40 patients with Crohn's disease (CD) and 37 patients with ulcerative colitis (UC) as well as from 19 healthy control individuals and 7 patients with infectious colitis. Disease activity was quantified by appropriate clinical disease indices and endoscopic scoring systems. RESULTS: When compared with healthy controls, miR-320a blood levels were significantly increased in patients with active CD and UC (16.1 ± 2.6 vs 2,573 ± 941; vs 434 ± 96; both P < 0.001) and patients with IBD in remission (316 ± 251 [CD] and 91 ± 29 [UC]; both P < 0.001). In patients with CD, miR-320a levels showed a strong correlation with the endoscopic disease activity (r(2) = 0.76; P < 0.001). Similarly, in patients with UC, we detected a significantly enhanced miR-320a expression, which was highest in patients with severe endoscopic disease activity (eMayo = 0–1: 66 ± 16 vs eMayo = 2: 352 ± 102; vs eMayo = 3: 577 ± 206; both P < 0.001). Finally, miR-320a blood expression in patients with active CD and UC significantly increased compared with patients with infectious colitis (63 ± 13, P < 0.001). DISCUSSION: MiR-320a expression in peripheral blood from patients with IBD follows the clinical and endoscopic disease activities and may help to distinguish IBD from infectious colitis. Wolters Kluwer 2020-03-17 /pmc/articles/PMC7145033/ /pubmed/32352717 http://dx.doi.org/10.14309/ctg.0000000000000134 Text en © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Cordes, Friederike Demmig, Claudia Bokemeyer, Arne Brückner, Markus Lenze, Frank Lenz, Philipp Nowacki, Tobias Tepasse, Phil Schmidt, Hartmut H. Schmidt, M. Alexander Cichon, Christoph Bettenworth, Dominik MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
title | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
title_full | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
title_fullStr | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
title_full_unstemmed | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
title_short | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
title_sort | microrna-320a monitors intestinal disease activity in patients with inflammatory bowel disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145033/ https://www.ncbi.nlm.nih.gov/pubmed/32352717 http://dx.doi.org/10.14309/ctg.0000000000000134 |
work_keys_str_mv | AT cordesfriederike microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT demmigclaudia microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT bokemeyerarne microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT brucknermarkus microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT lenzefrank microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT lenzphilipp microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT nowackitobias microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT tepassephil microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT schmidthartmuth microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT schmidtmalexander microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT cichonchristoph microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease AT bettenworthdominik microrna320amonitorsintestinaldiseaseactivityinpatientswithinflammatoryboweldisease |